Teva Pharmaceutical Industries Ltd.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2016 | $32.52B | $29.93B | $6.95B |
| FY2017 | $28.83B | $17.36B | $963.0M |
| FY2018 | — | $14.71B | $1.78B |
| FY2019 | — | $13.97B | $1.98B |
| FY2020 | — | $10.03B | $2.18B |
| FY2021 | — | $10.28B | $2.17B |
| FY2022 | — | $9.81B | $2.80B |
| FY2023 | — | $8.50B | $3.23B |
| FY2024 | — | $5.37B | $3.30B |
| FY2025 | — | $7.91B | $3.56B |